serum institute of india news]
Latest from serum institute of india
The Phase 1 and Phase 2 study of Dengusiil in India will be conducted on 45 adults of 18 years and above and 75 children of 2 years of age and above and less than (<) 18 years of age
Updated on Nov 27, 2023 05:08 AM IST
Cyrus Poonawalla, chairman of Serum Institute of India, suffered a mild cardiac arrest and underwent angioplasty. He is recovering and will be discharged soon.
Updated on Nov 17, 2023 10:37 PM IST
Cervavac vaccine to fight cervical cancer has been developed and manufactured by the Pune-based Serum Institute of India (SII)
Updated on Jul 18, 2023 12:54 AM IST
It is also the only vaccine that prevents meningitis caused by meningococcal group X, a pathogen increasingly implicated in meningitis outbreaks in Africa
The Top 10 companies in India hold ₹71.5 lakh crore, accounting for 37% of GDP. 7 of them are headquartered in Mumbai. Here is the list:
The Bombay High Court has restrained two social media influencers from posting defamatory content about Serum Institute of India, its CEO and their Covishield product in an interim application filed by SII in a defamation suit against the influencers. The court directed Yohan Tengra and Ambar Kori to remove the content from Twitter and YouTube. The SII claims the content posted by the duo about multiple deaths being due to the side effects of the vaccine was not only targeted at SII but also its CEO, and sought directions to Twitter and YouTube to take down defamatory content.
The order was passed in an interim application filed by SII in a defamation suit seeking ₹100 crore in damages from social media influencers Yohan Tengra and Ambar Kori for allegedly posting objectionable content regarding Covishield
Enforcement Directorate seizes properties worth INR 41.64 crore belonging to Zavaray Soli Poonawalla and family over foreign exchange violation probe linked to Panama Papers.
Updated on May 09, 2023 12:50 AM IST
, MumbaiAbhishek Sharan
The agency alleged that Zavareh Soli Poonawalla and his family members were accused of misuse of the Liberalised Remittance Scheme under the provisions of the Foreign Exchange Management Act.
According to a press release released by the British Deputy High Commission, India remains a priority market for the UK
SII has made available five to six million Covovax doses even as the demand for it is still almost zero. We will produce the same amount of Covishield doses in the next two to three months, said Adar Poonawalla
SII chief Adar Poonawalla on Saturday said that the current Covid strain is not severe and the company has produced five to six million doses of Covovax.
SII CEO Adar Poonawalla says Covishield manufacturing has resumed, 6M Covovax booster doses ready, and manufacturers are ready but no demand yet.
Published on Apr 12, 2023 05:38 PM IST
PTI | | Posted by Animesh Chaturvedi
Last month, COVID-19 Working Group also recommended to the health ministry inclusion of Covovax on the CoWIN portal as a heterologous booster dose for adults.
Published on Apr 03, 2023 08:10 PM IST
The R21 malaria vaccine, which is also known as Matrix-M, was designed at the Jenner Institute, University of Oxford, which collaborated with SII in 2020 to manufacture and develop the jab for large-scale supply.
As per the First Information Report registered with Bundgarden police station in the second week of September, the accused had used Poonawalla's image in a Whatsapp account and sent messages about money transfer to Satish Deshpande, one of the directors of the firm.
Published on Nov 25, 2022 07:32 PM IST
Adar Poonawalla's statement came even as the UK became the first country to authorise an updated version of Moderna's Covid-19 vaccine that includes protection against the Omicron variant.
India has so far reported eight cases of monkeypox, of which five have been from Kerala and three from Delhi. Of the five patients in Kerala, one succumbed to the disease on July 30, making it India's first monkeypox fatality.
Published on Aug 02, 2022 05:41 PM IST
Written by Sharangee Dutta | Edited by Aniruddha Dhar, New Delhi
SII manufactures Covovax under a license from the vaccine’s developer, US-based Novavax. The export version of the vaccine is called Nuvaxovid and has been dispatched to New Zealand, Netherlands, Australia and Indonesia, where a total of at least 100 million doses have been sent.
Cervical cancer in India ranks as the second most frequent cancer among women between 15 and 44 years of age.
Published on Jun 15, 2022 10:37 PM IST
On April 29, the National Technical Advisory Group on Immunisation (NTAGI)--the government’s technical panel--recommended inclusion of Covovax in the vaccination programme for children aged 12 and above.
Serum Institute of India (SII) director for government and regulatory affairs Prakash Kumar Singh had written to the Centre recently requesting for Covovax's inclusion in the immunisation drive for children aged 12 to 17 years.
Speaking to ANI, Poonawalla said, "The Covid-19 vaccines which have been made in India are providing more protection against the disease than mRNA vaccines like Pfizer and Moderna."
Published on Apr 13, 2022 04:22 PM IST
Covovax - which has not been formally announced as a booster shot, will be priced around ₹900 plus taxes, once approved. The vaccine is currently being used to inoculate adults and those in the 12-17 age group in emergency situations.
Submitting its reply to Puliyel’s petition in November last, the central drugs standard control organization (CDSCO) said that entertaining such a petition would harm public interest.
Serum Institute of India locally manufactures the Oxford-AstraZeneca Covid-19 vaccine under the brand name Covishield.
Serum Institute, which produces AstraZeneca's Covid-19 vaccine under the brand name Covishield, has supplied more than 1.25 billion doses of the shot in India.
Published on Dec 31, 2021 01:48 PM IST
Reuters | , Bengaluru
SII has the license to produce over two billion doses of the vaccine
The investment was made through the Indian company's Serum Life Sciences unit, Oxford University said on Wednesday.
Published on Dec 15, 2021 05:50 AM IST
The Pune-based SII had earlier on December 1 requested the DCGI to authorise Covishield as a booster dose, citing the emergence of new coronavirus variants in the country and an adequate stock of vaccines to tackle that growing concern.
Published on Dec 11, 2021 07:53 AM IST
Written by Joydeep Bose | Edited by Meenakshi Ray, Hindustan Times, New Delhi